Aviceda Therapeutics
MA - CambridgeBiotechnology
Focus: Aviceda Therapeutics is a Cambridge-based biotech company specializing in next-generation glyco-immune therapeutics, currently operating as a public company with a lean footprint of 1-50 employees.
Profile data last refreshed 18h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Employees
1-50
Total Funding
$100M
Open Jobs
0
About Aviceda Therapeutics
AI assessmentNot HiringNo open roles listed right now. Follow Aviceda Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
1 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
AVD-104
Diabetic Macular EdemaClinical Trials (2)
NCT05839041A Multiple Dose Study of AVD-104 for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
Phase 2Help build intelligence for Aviceda Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.